Damora Therapeutics (GLTO) Stock Analysis

What Damora Therapeutics does

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Key metrics

ETFs linked to GLTO

Broad-market and Healthcare sector ETFs an investor holding Damora Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GLTO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Damora Therapeutics?

Damora Therapeutics trades under the ticker GLTO on NASDAQ.

Which exchange is GLTO listed on?

GLTO is listed on NASDAQ.

What sector does Damora Therapeutics operate in?

Damora Therapeutics is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze GLTO in a portfolio?

PortView shows GLTO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.